logo
  

Gilead: Week 48 Findings Underscore Efficacy Of Bulevirtide For Treatment Of Chronic HDV

Gilead Sciences, Inc. (GILD) reported week 48 results from the phase 3 trial evaluating Hepcludex or bulevirtide for the treatment of chronic hepatitis delta virus infection. The company said these data reinforce the clinical utility of bulevirtide as monotherapy for the treatment of chronic hepatitis delta virus. The data showed the positive impact of bulevirtide on patient-reported outcomes. The safety profile of bulevirtide at week 48 is consistent with prior reports.

Bulevirtide was granted Conditional Marketing Authorization by the European Commission and is an investigational agent in the U.S. and outside of the European Economic Area. Bulevirtide has been granted Breakthrough Therapy and Orphan Drug designations by the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT